92013-31-5

Basic information

• Product Name: 5-BROMO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL
• Synonyms: 5-BROMO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL
• CAS NO: 92013-31-5
• Molecular Formula: C₁₀H₁₁BrO
• Molecular Weight: 227.1
• Mol File: 92013-31-5.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-BROMO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL(92013-31-5)
• EPA Substance Registry System: 5-BROMO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL(92013-31-5)

Safety Data

• Hazardous Substances Data: 92013-31-5(Hazardous Substances Data)

Usage

General Description

5-BROMO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL is a chemical compound with the formula C10H13BrO. It is a brominated derivative of tetrahydronaphthalen-1-ol, with a molecular weight of 235.11 g/mol. 5-BROMO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL is commonly used as a building block in organic synthesis and pharmaceutical research, as well as in the production of fragrance and flavor compounds. It is a white to off-white crystalline solid that is soluble in organic solvents and has a characteristic odor. 5-BROMO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL is a versatile chemical with a wide range of applications in various industries.

Upstream product

• 68449-30-9 5-bromo-1-tetralone 
• 1074-15-3 1-bromo-2-(2-bromoethyl)benzene 
• 19472-74-3 2-(2-bromophenyl)acetonitrile 
• 18698-97-0 ortho-bromophenylacetic acid 
• 1074-16-4 2-bromophenylethyl alcohol 
• 92013-28-0 1,1-bis(ethoxycarbonyl)-3-(2'-bromophenyl)propane 
• 90841-47-7 4-(2-bromophenyl)butanoic acid 
• 92013-30-4 4-(o-bromophenyl)butyryl chloride 
• 92013-29-1 2-(2-(o-bromophenyl)ethyl)-malonic acid 
• 3433-80-5 1-Bromo-2-bromomethyl-benzene 
• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 

Downstream Products

• 87779-57-5 bromo-5 dihydro-3,4 naphthalene 
• 42775-75-7 5-ethyltetralin 
• 66325-42-6 5-n-butyltetralin 
• 132095-53-5 5-Bromo-2-oxo-1,2,3,4-tetrahydronaphthalene 

Relevant articles and documents

SEROTONIN RECEPTOR MODULATORS

Compounds, compositions, and methods are provided for dual partial agonism of serotonin 5-HT7 and 5-HT1A receptors. The enantiomerically pure 5-phenyl-2-aminotetralin (5-PAT) compounds can be used to treat or prevent substance use disorder, opioid use disorder, addiction, anxiety, psychosis, depression, autism spectrum disorder, fragile X syndrome, neurological disorders, neuropsychiatric disorders, repetitive behaviors, movement disorders, compulsions, tics, pain disorders, vasospastic disorders, migraine headache, seizures, epilepsy, social anxiety, addiction withdrawal, drug withdrawal, drug abuse, alcoholism, eating disorders, general inflammation disorders, miosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, and gastrointestinal disorders.

COMPOUNDS AND METHODS FOR MODULATING SEROTONIN RECEPTORS IN THE PERIPHERY

This invention relates to, in part, compositions and methods that are useful for, inter alia, the treatment of various diseases, including those linked to binding at a serotonin receptor in the Gl tract.

Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968)

Various racemic and enantioenriched (trans)-X,Y-dihydroxy-X,Y-dihydronaphthoyl analogues as well as X-hydroxy-naphthoyl analogues of CRTh2 antagonist 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (1, Setipiprant/ACT-129968) were synthesized in order to gain insight into regio- and enantioselectivity of the metabolic oxidation of 1 and to verify the structures of four metabolites that were proposed earlier in a clinical ADME study. Analytical data of the synthetic standards were compared with data from samples of biological origin. The two major metabolites M7 and M9 were unambiguously verified as 2-(2-((trans)-3,4-dihydroxy-3,4-dihydronaphthalene-1-carbonyl)- and 2-(2-((trans)-5,6-dihydroxy-5,6-dihydronaphthalene-1-carbonyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid, respectively, each composed of two enantiomers with 68% and 44% ee in favor of (+)-(3S,4S)-M7 and (+)-(5S,6S)-M9, respectively. Likewise, minor metabolites M3 and M13 were identified as 2-(8-fluoro-2-(5-hydroxy-1-naphthoyl)- and 2-(8-fluoro-2-(4-hydroxy-1-naphthoyl)-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-5-yl)acetic acid, respectively.